Ethiopian Pharmaceutical Manufacturing Sh. Co.

Belkins
The Ethiopian Pharmaceuticals Manufacturing Sh. Co. (EPHARM) is a pioneer in the pharmaceutical manufacturing industry of Ethiopia. It is now 52 years old. It had been the only pharmaceutical manufacturer for more than 36 years in the country. It’s headquarter is located in Nifas Silk Lafto subcity, Addis Ababa. EPHARM is currently producing different dosage forms, which makes it peculiar from many of the local pharmaceutical manufacturers. EPHARM has been producing high quality and affordable medicine that have addressed the critical health problems of the Ethiopian people for more than fifty years. The products encompass; Antibiotics, Infusions, Topical drugs, Drugs that act on central nervous system (CNS), Gastroenterological drugs, Vitamins, Anti-Allergic, Analgesics, Anti- Tussives and many more.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

POINT-OF-CARE TOOLS IN PHARMACY TAKE OFF

Managed Healthcare Executive | March 02, 2020

news image

New point-of-care (POC) tools that promote communication between providers and patients are establishing themselves as next generation shared decision-making solutions, especially when it comes to medications and issues of insurance coverage, price, and out-of-pocket costs. “When compared to traditional shared decision-making tools, there’s an increased emphasis not just on improving measures such as medication adherence by involving the patient in his or her own care but also on usi...

Read More

PARALLEL'S SURTERRA WELLNESS STORES TO INTRODUCE NEW PRODUCTS INCLUDING EDIBLES IN FLORIDA

Prnewswire | August 31, 2020

news image

Parallel, formerly known nationally as Surterra Holdings, a company pioneering well-being through its proprietary cannabinoid brands, science and technology-led innovation, today announced that it will introduce new edible cannabis products to its customers in its 39 Florida Surterra Wellness stores. This expansion of Surterra Wellness' product offering follows the Florida Department of Health's (FDOH) finalizing recently released emergency rules to allow for the production and sale of e...

Read More

PHARMA TECH

INVITAE TO ACQUIRE CIITIZEN TO STRENGTHEN ITS PATIENT-CONSENTED HEALTH DATA PLATFORM TO IMPROVE PERSONAL OUTCOMES AND GLOBAL RESEARCH

Invitae | September 07, 2021

news image

Invitae , a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z, Section 32 and Verily, Ciitizen is working to build a global platform to help patients collect, organize, store and share their medical records digitally. The acquisition would enhance Invitae's platform by providing patients an easy-to-use, centralized hub for their genomic and clinical information, whic...

Read More

AZ RECRUITS IMAGINAB IN CD8 IMMUNOPET DEAL

PharmaTimes | March 30, 2020

news image

AstraZeneca has revealed plans to signed a multi-year non-exclusive license agreement with ImaginAb, in order to license the latter’s ImaginAb’s CD8 ImmunoPET technology. The companies say that under the terms of the agreement, the technology will be used in AstraZeneca’s clinical trials in Europe and North America to facilitate clinical development of AstraZeneca’s novel immunotherapies and to advance the clinical utility of ImaginAb’s CD8 ImmunoPET. CD8 ImmunoPET ...

Read More
news image

POINT-OF-CARE TOOLS IN PHARMACY TAKE OFF

Managed Healthcare Executive | March 02, 2020

New point-of-care (POC) tools that promote communication between providers and patients are establishing themselves as next generation shared decision-making solutions, especially when it comes to medications and issues of insurance coverage, price, and out-of-pocket costs. “When compared to traditional shared decision-making tools, there’s an increased emphasis not just on improving measures such as medication adherence by involving the patient in his or her own care but also on usi...

Read More
news image

PARALLEL'S SURTERRA WELLNESS STORES TO INTRODUCE NEW PRODUCTS INCLUDING EDIBLES IN FLORIDA

Prnewswire | August 31, 2020

Parallel, formerly known nationally as Surterra Holdings, a company pioneering well-being through its proprietary cannabinoid brands, science and technology-led innovation, today announced that it will introduce new edible cannabis products to its customers in its 39 Florida Surterra Wellness stores. This expansion of Surterra Wellness' product offering follows the Florida Department of Health's (FDOH) finalizing recently released emergency rules to allow for the production and sale of e...

Read More
news image

PHARMA TECH

INVITAE TO ACQUIRE CIITIZEN TO STRENGTHEN ITS PATIENT-CONSENTED HEALTH DATA PLATFORM TO IMPROVE PERSONAL OUTCOMES AND GLOBAL RESEARCH

Invitae | September 07, 2021

Invitae , a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z, Section 32 and Verily, Ciitizen is working to build a global platform to help patients collect, organize, store and share their medical records digitally. The acquisition would enhance Invitae's platform by providing patients an easy-to-use, centralized hub for their genomic and clinical information, whic...

Read More
news image

AZ RECRUITS IMAGINAB IN CD8 IMMUNOPET DEAL

PharmaTimes | March 30, 2020

AstraZeneca has revealed plans to signed a multi-year non-exclusive license agreement with ImaginAb, in order to license the latter’s ImaginAb’s CD8 ImmunoPET technology. The companies say that under the terms of the agreement, the technology will be used in AstraZeneca’s clinical trials in Europe and North America to facilitate clinical development of AstraZeneca’s novel immunotherapies and to advance the clinical utility of ImaginAb’s CD8 ImmunoPET. CD8 ImmunoPET ...

Read More